Fujirebio & Randox in cancer assay deal:
This article was originally published in Clinica
Executive Summary
Fujirebio Diagnostics (FDI) is collaborating with UK firm Randox Laboratories on the development of cancer diagnostic assays that will employ FDI's cancer marker antibodies and Randox' automated biochip array technology. Crumlin, Northern Ireland-based Randox' array technology permits the simultaneous determination of a panel of diagnostic markers from just a single patient sample. Multiplexing - using several biomarkers together - may help detect disease at an earlier, more treatable stage, said FDI, of Malvern, Pennsylvania firm (see Clinica No 1018, p 17).